Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the use of antibody-drug conjugates such as enfortumab vedotin and sacituzumab govetican for patients with advanced bladder cancer, and the need to research the optimal sequencing of these agents. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.